Study of Chiglitazar Compare With Placebo in Type 2 Diabetes Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 535 participants.

Also called NCT02121717

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 535 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02121717
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02121717. Randomized; double masking; primary purpose treatment. Start 2014-06 (registry gives no type); primary completion 2017-11 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of Chiglitazar Compare With Placebo in Type 2 Diabetes Patients
Acronym
CMAP
Intervention (Drug)
Chiglitazar
Intervention (Drug)
Placebo
Lead sponsor
Chipscreen Biosciences, Ltd. (class: industry)

Record details

Record id
cardio:ct-nct02121717
Content hash
41d6e525cd82685502d1f26683164b19c5bd026ebf74757baafe2a20511fe98c